"Cancer vaccine revolution" seeing most striking data from Northwest Biotherapeutics, says analyst

Pharmaceuticals and biotechnology analyst Navid Malik of the London-based Matrix Group, as part of an in-depth review of the history and competitive landscape of what he calls the "cancer vaccine revolution," concludes that Northwest Biotherapeutics (NWBT)' has generated some of the most striking data on survival and delayed time to progression in both brain cancer and prostate cancer that we have seen from any product in the market or in clinical development."

Citing both "high dendritic cell purity" and "the single-batch bulk manufacturing process," as "key advantages of NWBT's technology which have not yet been appreciated by the market," he concludes that this gives the firm's DCVax a "competitive advantage'versus virtually all of the other personalized cancer vaccine players."

Other key conclusions from Dr Malik's newly-released report include: